<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-Nov</td>
<td>12:00 - 12:00 AM</td>
<td></td>
<td>Defining the Bioenergetic Metabolite Interactome in Human Subjects</td>
<td>Victor Darley-Usmar, Ph.D. Associate Dean for Research, Endowed Professor in Mitochondrial Medicine and Pathology, University of Alabama at Birmingham</td>
</tr>
<tr>
<td>30-Nov</td>
<td>12:00 - 12:00 AM</td>
<td></td>
<td>Metabolic regulation of adaptive immune cell function</td>
<td>Sandra Milasta, PhD Senior Scientist, Immunotherapy, Pre-clinical Development, Elevatebio</td>
</tr>
<tr>
<td>9-Dec</td>
<td>11:30 - 12:30 PM</td>
<td>QUBES: A rapid approach for predicting the stability of proteins</td>
<td>QUBES: A rapid approach for predicting the stability of proteins</td>
<td>Chris Pudney, PhD Associate Professor of Biophysics, University of Bath; Director, BLOC Laboratories Ltd</td>
</tr>
<tr>
<td>9-Dec</td>
<td>01:00 - 02:00 PM</td>
<td>Using Physical Chemistry and a High-Throughput Drug Screen to Find a Drug to Treat Sickle Cell Disease</td>
<td>Using Physical Chemistry and a High-Throughput Drug Screen to Find a Drug to Treat Sickle Cell Disease</td>
<td>Emily Dunkelberger, PhD Staff Scientist, Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health</td>
</tr>
<tr>
<td>10-Dec</td>
<td>11:30 - 12:30 PM</td>
<td></td>
<td>Mechanism-based Off-target Screening De-risks Clinical Development of Antiviral Nucleoside/tide Drugs</td>
<td>Joy Feng, PhD Principal Scientist, Gilead Sciences, Inc.</td>
</tr>
<tr>
<td>10-Dec</td>
<td>01:00 - 02:00 PM</td>
<td></td>
<td>Using an unbiased drug discovery platform to uncover a novel immunogenic cell death</td>
<td>Charly Chahwan, PhD Co Founder, CSO at SyntheX, Inc.</td>
</tr>
</tbody>
</table>